https://www.selleckchem.com/mTOR.html
More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphoma. We studied the effects of ceritinib treatment in NPM1-ALK+ T-cell lymphoma cell lines invitro and on tumor size and survival advantage invivo utilizing tumor xenografts. We treated an NPM1-ALK+ ALCL patient with ceritinib. We reviewed all hematologic malignancies
Gefällt mir
Kommentar
Teilen
